Early posttransplant rituximab use in kidney transplant recipients with preexisting donor-specific antibodies.

Although recipients treated with rituximab tended to experience fewer rejection episodes and lower rates of elevated donor-derived cell-free DNA, these differences did not reach statistical significance.

also in 111,027 other papers